Omics In Health

Battelle leverages advanced omics technologies, including genomics, transcriptomics, epigenomics, proteomics, and microbiomics, to address critical health challenges in diagnostics, drug development, and personalized medicine. By combining expertise in next-generation sequencing (NGS), high-resolution mass spectrometry, machine learning, and bioinformatics, Battelle provides actionable insights to drive innovation across the pharmaceutical and biotechnology industries.

Their integrated approach enables comprehensive profiling of DNA, RNA, proteins, and microbial communities, supporting applications such as biomarker discovery, assay validation, pathogen detection, and personalized treatments. Battelle also specializes in analyzing drug mechanisms, studying disease pathways, and conducting pre-clinical and clinical sample analyses. This holistic methodology extends beyond basic sequencing to identify low-frequency mutations, emerging pathogens, and predictive disease biomarkers.

Battelle’s proprietary curated database and advanced analytical tools enable accurate data interpretation, including identifying contaminants in pharmaceutical manufacturing, as demonstrated by a case study where they avoided costly disruptions by correctly identifying a benign organism mistaken for a harmful pathogen.

Applications include identifying genes linked to genetic diseases, profiling chemical exposures, evaluating vaccine effectiveness, and assessing environmental impacts on health. Their expertise in multi-omics fosters a deeper understanding of molecular mechanisms driving health outcomes, enabling clients to develop novel diagnostics and targeted therapies.

With decades of R&D experience, Battelle empowers clients to translate complex omics data into actionable solutions, accelerating advancements in healthcare and biotechnology while ensuring data accuracy and reliability.